Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.

Physiological genomics - 1 Feb 2018

Dempsey Jacqueline M, Xi Jingyue, Henry N Lynn, Rae James M, Hertz Daniel L

Abstract excerpt

Aromatase inhibitor (AI) therapy is highly efficacious in the treatment of estrogen receptor-positive breast cancer; however, in a subset of patients AI use is discontinued due to drug-induced musculoskeletal adverse events (MS-AE). Several studies have investigated the role of germline single nucleotide polymorphisms (SNPs) on patients' risk of MS-AEs; however, no associations have yet to be validated for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Aromatase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Genetic Predisposition to Disease

Share to Osteoprotegerin

Share to Polymorphism, Single Nucleotide

Share to RANK Ligand

Source

Open in PubMed Open full text

Identifiers

PMID: 29212847
DOI: 10.1152/physiolgenomics.00085.2017
PMCID: PMC5867615

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.PMID 29212847Read ↗

RANKL and OPG Polymorphisms Are Associated with Aromatase Inhibitor-Related Musculoskeletal Adverse Events in Chinese Han Breast Cancer Patients.Semantic proximity Read ↗

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.Semantic proximity Read ↗

Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.Semantic proximity Read ↗

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.Semantic proximity Read ↗

Genetic variant in the osteoprotegerin gene is associated with aromatase inhibitor-related musculoskeletal toxicity in breast cancer patients.Semantic proximity Read ↗

Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associations.Semantic proximity Read ↗

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.Semantic proximity Read ↗

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.Semantic proximity Read ↗

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.Semantic proximity Read ↗

ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.Semantic proximity Read ↗

Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptomsSemantic proximity Read ↗

Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.